FREQUENTLY ASKED QUESTIONS

PRIME is a clinical stage research and development company developing next generation vaccines both, for humans and animals. We offer technology licenses for existing and customer-specific vaccination vectors for the prevention and therapy of infectious diseases and cancer.

Our vaccines are based on an attenuated Orf virus (ORFV), which is proven to be safe and well tolerated by humans. We utilize this particular virus as a platform technology to design and generate vaccination vectors comprising tumor- or pathogen-specific information. These vaccination vectors deliver the information to specifically activate the immune system and prevent from, or treat an existing disease. Further, the ORFV platform allows for the integration of accessory information that can further increase the immune response (e.g. cytokines, activation signals, and/or checkpoint antibodies in a modular design).

PRIME’s safe platform technology combines the advantages of alternative vaccine technologies and adds even more:

• Our vaccine vectors address antigen presenting cells (APCs) as key players of the immune system. Using our vaccine vectors, APCs can be orchestrated to induce potent and specific B-cell, but especially T-cell responses important for effective cancer therapy.

• ORFV possesses favorable inherent immunostimulatory properties, which make the use of additional adjuvants redundant in order to strongly activate the immune system.

• Due to absence of ORFV specific neutralizing antibodies (lack of anti-vector immunity), our vaccination vectors can be administered repeatedly in the same individual without loss of efficacy.

• Belonging to the family of poxviruses, ORFV comprises a large capacity for transgene insertion. This allows the combination of target antigens in a single vectored, multivalent vaccine without increasing toxicity.

• PRIME's vaccine vectors offer technical and logistical advantages including scalable manufacturing using an established GMP compliant CMC process, and stability at higher temperatures for improved vaccine availability and distribution.

PVT has followed an extensive testing strategy to identify the most potent, multivalent vaccine candidate to address the COVID-19 pandemic. Preclinical data has shown our lead vaccine candidate Prime-2-CoV to induce highly potent immune responses against all encoded antigens and protection to challenge infection in several model organisms including non-human primates. Currently, the vaccine is being tested in phase I clinical trials.